These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11055241)

  • 1. MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-alpha.
    Meier V; Mihm S; Ramadori G
    J Med Virol; 2000 Nov; 62(3):318-26. PubMed ID: 11055241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha.
    Jorns C; Holzinger D; Thimme R; Spangenberg HC; Weidmann M; Rasenack J; Blum HE; Haller O; Kochs G
    J Med Virol; 2006 Jan; 78(1):74-82. PubMed ID: 16299717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of clinical evidence for involvement of hepatitis C virus interferon-alpha sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses.
    Mihm S; Monazahian M; Grethe S; Meier V; Thomssen R; Ramadori G
    J Med Virol; 2000 May; 61(1):29-36. PubMed ID: 10745229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection.
    Naarendorp M; Kallemuchikkal U; Nuovo GJ; Gorevic PD
    J Rheumatol; 2001 Nov; 28(11):2466-73. PubMed ID: 11708420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
    Srinivas D; Mani H; Crumpler C; Van Thiel DH
    Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes.
    Meier V; Mihm S; Ramadori G
    J Med Virol; 2008 Nov; 80(11):1912-8. PubMed ID: 18814253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.
    Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H
    J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C.
    Xu DZ; Xie Y; Li ZQ
    Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):550-3. PubMed ID: 16286260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of serum levels of HCV RNA in early phase of IFN therapy; as a predictive marker of subsequent response.
    Yamakawa Y; Sata M; Suzuki H; Tanaka K; Tanaka E; Noguchi S; Ono K; Tanikawa K
    Hepatogastroenterology; 1998; 45(19):133-6. PubMed ID: 9496502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease.
    Gigi E; Raptopoulou-Gigi M; Kalogeridis A; Masiou S; Orphanou E; Vrettou E; Lalla TH; Sinakos E; Tsapas V
    J Viral Hepat; 2008 Feb; 15(2):145-54. PubMed ID: 18184198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.